ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

“Action Steps” Listed For Prostate Research In National Blueprint

January 16, 1998

“Honor Roll” Of Top Investigators Who Won’t Be Funded Because Of Cuts

March 8, 1985

NIH begins transition to electronic grant submissions; seeks comment on options for NRSA funding.

October 28, 2005

Government Shutdown Cancels NCI Site Visit To Mayo Cancer Center

October 11, 2013

In Brief: Changes In Key Subcommittee chairmanships, Brooke’s Defeat Leave Direction In Doubt

November 17, 1978

NCI Advisory Group, Other Cancer Meetings For Feb., March Listed

January 25, 1991